Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations
Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the many new drugs that have come on the market recently to treat prostate cancer. The many new agents call for a closer look into combination therapies.
These new therapies have multiple mechanisms of actions such as the immunotherapy sipuleucel-T (Provenge), the radiopharmaceutical radium-223 (Alpharadin), hormonal or androgen deprivation therapies such as abiraterone acetate (Zytiga), and chemotherapy agents.
The goal of research is to take these agents from a sequencing scenario and develop combination therapies. The varying mechanisms of actions make each of these agents unique and allows for interesting combinations.